Novavax, Inc.
Novavax, Inc. (NVAX) is a clinical‑stage biotechnology company focused on developing protein‑based vaccines, best known for its COVID‑19 vaccine candidate NVX‑CoV2373. Investors should know Novavax’s fortunes are closely tied to the progress of its pipeline, contract and grant revenues, and its ability to secure regulatory approvals and manufacturing scale. The company has a history of funding rounds and collaborations with governments and partners, which can boost near‑term cash flow but also create revenue lumpiness. Key risks include clinical trial outcomes, regulatory decisions, competitive vaccine platforms, and the need for additional capital to support R&D and commercialisation. With a market capitalisation of about $1.40B, Novavax may offer growth upside for those who believe in its technology, but it is also a higher‑volatility, higher‑risk equity more suitable for investors comfortable with biotech uncertainty. This is educational information, not personalised investment advice.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Novavax's stock with a target price of $12.67, indicating potential growth.
Financial Health
Novavax is generating strong revenue and cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NVAX
Pediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: July 1, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline and R&D
Novavax's future depends on clinical progress and approvals; successful trials can drive value, though outcomes are uncertain and can affect share price sharply.
Contract‑Led Revenue
Government and partner deals have been a major revenue source, offering near‑term visibility but also creating lumpiness and dependence on external funding.
Manufacturing & Scale
Scaling production is central to commercial success; manufacturing or supply hiccups can delay launches and revenue, so operational risk is material.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
